Want to see CH:BANB full AI Analyst Report?
Top Page
Bachem Holding AG
(BANB)
Select Model
Select Model
Rating:74Outperform
Price Target:
CHF94.00
▲(24.09% Upside)
Action:Upgraded
Date:10/22/26
The score is driven primarily by strong financial quality (solid profitability and a very low-leverage balance sheet), supported by positive technical momentum. These strengths are tempered by persistent negative free cash flow and a high valuation multiple with only a modest dividend yield.
Positive Factors
Very low leverage
The exceptionally conservative capital structure reduces financial strain and preserves flexibility for capacity investment, customer programs, or downturns. A large and growing equity base also supports resilience because profitability is not dependent on heavy borrowing or leverage.
Negative Factors
Persistent negative free cash flow
Repeated negative free cash flow means substantial investment spending or working-capital needs are absorbing internally generated cash. If this pattern persists, Bachem may have less flexibility to fund expansion, dividends, or other strategic priorities without relying on external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage
The exceptionally conservative capital structure reduces financial strain and preserves flexibility for capacity investment, customer programs, or downturns. A large and growing equity base also supports resilience because profitability is not dependent on heavy borrowing or leverage.
Read all positive factors
Bachem Holding AG (BANB) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF6.45B
Dividend Yield1.07%
Average Volume (3M)91.00K
Price to Earnings (P/E)42.3
Beta (1Y)0.77
Revenue Growth4.51%
EPS Growth11.05%
CountryCH
Employees2,725
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)1.99
Shares Outstanding75,000,000
10 Day Avg. Volume87,663
30 Day Avg. Volume91,004
Financial Highlights & Ratios
PEG Ratio1.27
Price to Book (P/B)3.08
Price to Sales (P/S)6.46
P/FCF Ratio-93.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF83.60Price Target Upside10.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)2.4
Revenue Forecast (FY)CHF942.18M
Bachem Holding AG Business Overview & Revenue Model
Company Description
Bachem Holding AG serves pharmaceutical and biotechnology companies globally, providing products crucial for research, clinical development, and commercial use. The company's primary focus is on the design, manufacturing, and regulatory support fo...
How the Company Makes Money
Bachem primarily makes money by providing contract development and manufacturing services and by supplying peptide- and oligonucleotide-related products to pharmaceutical and biotech customers. Key revenue streams include: (1) CDMO services (devel...
Bachem Holding AG Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
90
Very Positive
Cash Flow
55
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 708.53M | 695.07M | 605.26M | 577.32M | 531.74M | 503.23M |
| Gross Profit | 191.33M | 199.73M | 182.56M | 176.96M | 171.28M | 166.73M |
| EBITDA | 189.55M | 197.72M | 178.76M | 166.74M | 160.54M | 156.47M |
| Net Income | 148.96M | 148.79M | 120.25M | 111.86M | 100.68M | 114.68M |
Balance Sheet | ||||||
| Total Assets | 2.34B | 2.11B | 1.92B | 1.68B | 1.38B | 1.30B |
| Cash, Cash Equivalents and Short-Term Investments | 51.57M | 30.99M | 95.20M | 298.53M | 268.43M | 442.36M |
| Total Debt | 208.10M | 57.39M | 290.00K | 401.00K | 691.00K | 20.86M |
| Total Liabilities | 895.36M | 650.41M | 531.88M | 362.36M | 214.21M | 177.50M |
| Stockholders Equity | 1.44B | 1.46B | 1.39B | 1.32B | 1.17B | 1.12B |
Cash Flow | ||||||
| Free Cash Flow | -47.40M | -48.20M | -138.30M | -18.54M | -49.76M | -19.66M |
| Operating Cash Flow | 289.92M | 271.36M | 146.32M | 249.86M | 92.59M | 97.16M |
| Investing Cash Flow | -344.43M | -325.22M | -148.88M | -170.81M | -63.17M | -469.13M |
| Financing Cash Flow | 76.87M | -9.52M | -61.26M | 48.69M | -86.93M | 437.58M |
Bachem Holding AG Technical Analysis
Positive
75.75
Price Trends
79.17
Positive
75.78
Positive
71.33
Positive
Market Momentum
1.38
Negative
54.13
Neutral
75.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:BANB, the sentiment is Positive. The current price of 75.75 is below the 20-day moving average (MA) of 81.51, below the 50-day MA of 79.17, and above the 200-day MA of 71.33, indicating a bullish trend. The MACD of 1.38 indicates Negative momentum. The RSI at 54.13 is Neutral, neither overbought nor oversold. The STOCH value of 75.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:BANB.
Bachem Holding AG Peers Comparison
UnderperformOutperform
Sector (55)
CH:BANB
Bachem Holding AG
82.55
25.73
45.29%
CH:LONN
Lonza Group Ltd
628.20
60.16
10.59%
Bachem Holding AG Corporate Events
Bachem boosts sales, ramps up capacity for peptide and oligonucleotide growth
Jul 30, 2026
Bachem Holding AG reported first-half 2026 sales of CHF 326.4 million, up 4.3% year-on-year, while EBITDA declined 9% as ramp-up costs for its new large-volume Building K facility weighed on margins. The company saw strong growth in clinical activ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.